Preliminary Study of Microwave Tumoral Ablation Performances for the Treatment of Pulmonary, Renal and Bone Neoplasia.

The aims of this work were to assess the feasibility, efficacy, short-term outcome and safety of microwave ablation in the treatment of malignant bone, lung and renal tumors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Tumor Adenocarcinoma Bone Diseases Bone Neoplasms Bone Tumor Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Lung Diseases Lung Neoplasms Male Urogenital Diseases Musculoskeletal Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Renal Tumor Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

CHU Besançon

Besançon, 25000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men and women > 18 years old
Thermoablation indication of renal neoplasia, bone or lung decided during a multidisciplinary consultation meeting - Generally speaking, the indications are: (i) inoperable primary malignant tumor or secondary malignant tumor, (ii) resectable primary malignant renal and lung tumor with medical contraindication to surgery or general anesthesia
Signature of informed consent for participation
Affiliation to a social security scheme or French beneficiary of such a regime.

Exclusion criteria

Contraindication to percutaneous thermoablation
Renal or lung tumor up to 4 cm
Women of childbearing age, premenopausal, non-sterilized surgically, and unwilling to use effective contraception
Legal incapacity or legal capacity limited
Person unlikely to cooperate in the study and / or low degree of cooperation expected by the investigator
Person without health insurance
Pregnant women

Treatment and study plan

Microwave ablation with Acculis Accu2i pMTA Applicator

Device

Primary outcomes

Tumor necrosis rate in post-intervention over one month monitoring period.

Time frame: one month

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Besancon

Other

Registry information

Acronym: TherMO

Important dates

Study start: 2012
Primary completion: 2015
Study completion: 2015
First posted: Aug 11, 2016
Registry last updated: Aug 11, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed